"FAR" chemoradiotherapy improves laryngeal preservation rates in patients with T2N0 glottic carcinoma.

Background: The appropriate treatment approach for patients with T2N0 laryngeal cancer remains highly controversial. Because radiotherapy alone is associated with a high risk of local recurrence, we have developed a triple combination treatment approach consisting of 5-fluorouracil (250 mg/day, i.v.